The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

DIMETHYLTRYPTAMINE     2-(1H-indol-3-yl)-N,N- dimethyl-ethanamine

Synonyms: CHEMBL12420, SureCN335710, AG-G-24189, AG-G-65372, CHEBI:28969, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of DIMETHYLTRYPTAMINE

 

Psychiatry related information on DIMETHYLTRYPTAMINE

  • Several opioid agonists and antagonists interact with N,N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) in adult male Holtzman rats trained on a positive reinforcement, fixed ratio 4 (FR4) behavioral schedule, i.e., a reward of 0.01 ml sugar-sweetened milk was earned on every fourth bar press [6].
 

High impact information on DIMETHYLTRYPTAMINE

 

Biological context of DIMETHYLTRYPTAMINE

 

Anatomical context of DIMETHYLTRYPTAMINE

 

Associations of DIMETHYLTRYPTAMINE with other chemical compounds

 

Gene context of DIMETHYLTRYPTAMINE

 

Analytical, diagnostic and therapeutic context of DIMETHYLTRYPTAMINE

References

  1. Urinary excretion of dimethyltryptamine in liver disease. Checkley, S.A., Oon, M.C., Rodnight, R., Murphy, M.P., Williams, R.S., Birley, J.L. The American journal of psychiatry. (1979) [Pubmed]
  2. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., Barbanoj, M.J. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  3. A simple and sensitive quantitation of N,N-dimethyltryptamine by gas chromatography with surface ionization detection. Ishii, A., Seno, H., Suzuki, O., Hattori, H., Kumazawa, T. Journal of analytical toxicology. (1997) [Pubmed]
  4. The pathogenesis of the nervous syndrome of Phalaris aquatica toxicity in sheep. Bourke, C.A., Carrigan, M.J., Dixon, R.J. Aust. Vet. J. (1990) [Pubmed]
  5. Effects of iproniazid, chlorpromazine and methiothepin on DMT-induced changes in body temperature, pupillary dilatation, blood pressure and EEG in the rabbit. Moore, R.H., Demetriou, S.K., Domino, E.F. Archives internationales de pharmacodynamie et de thérapie. (1975) [Pubmed]
  6. Effects of selected opioid agonists and antagonists on DMT- and LSD-25-induced disruption of food-rewarded bar pressing behavior in the rat. Ruffing, D.M., Domino, E.F. Psychopharmacology (Berl.) (1981) [Pubmed]
  7. Letter: Urinary dimethyltryptamine in psychiatric patients. Oon, M.C., Murray, R.H., Brockington, I.F., Rodnight, R., Birley, J.L. Lancet (1975) [Pubmed]
  8. Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association. Murray, R.M., Oon, M.C., Rodnight, R., Birley, J.L., Smith, A. Arch. Gen. Psychiatry (1979) [Pubmed]
  9. Methylation hypothesis. Baldessarini, R.J., Stramentinoli, G., Lipinski, J.F. Arch. Gen. Psychiatry (1979) [Pubmed]
  10. Rabbit lung indolethylamine N-methyltransferase. cDNA and gene cloning and characterization. Thompson, M.A., Weinshilboum, R.M. J. Biol. Chem. (1998) [Pubmed]
  11. A test of the transmethylation hypothesis in acute schizophrenic patients. Carpenter, W.T., Fink, E.B., Narasimhachari, N., Himwich, H.E. The American journal of psychiatry. (1975) [Pubmed]
  12. Human psychopharmacology of N,N-dimethyltryptamine. Strassman, R.J. Behav. Brain Res. (1996) [Pubmed]
  13. Detection and determination of abused hallucinogens in biological material. Ondra, P., Zednikova, K., Valka, I. Neuro Endocrinol. Lett. (2006) [Pubmed]
  14. Variation in the accumulation levels of N,N-dimethyltryptamine in micropropagated trees and in in vitro cultures of Mimosa tenuiflora. Nicasio, M.d.e.l. .P., Villarreal, M.L., Gillet, F., Bensaddek, L., Fliniaux, M.A. Nat. Prod. Res. (2005) [Pubmed]
  15. Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry. Smythies, J.R., Morin, R.D., Brown, G.B. Biol. Psychiatry (1979) [Pubmed]
  16. Opposite effects of N,N-dimethyltryptamine (DMT) and 5-methoxy-n,n-dimethyltryptamine (5-MeODMT) on acoustic startle: spinal vs brain sites of action. Commissaris, R.L., Davis, M. Neuroscience and biobehavioral reviews. (1982) [Pubmed]
  17. A new metabolic pathway for N,N-dimethyltryptamine. Hryhorczuk, L.M., Rainey, J.M., Frohman, C.E., Novak, E.A. Biol. Psychiatry (1986) [Pubmed]
  18. Influence of psychotomimetics and lisuride on synaptosomal dopamine release in the nucleus accumbens of rats. Hetey, L., Schwitzkowsky, R., Oelssner, W. Eur. J. Pharmacol. (1983) [Pubmed]
  19. Hallucinogenic drugs are partial agonists of the human platelet shape change response: a physiological model of the 5-HT2 receptor. McClue, S.J., Brazell, C., Stahl, S.M. Biol. Psychiatry (1989) [Pubmed]
  20. Factors affecting the urinary excretion of endogenously formed dimethyltryptamine in normal human subjects. Oon, M.C., Murray, R.M., Rodnight, R., Murphy, M.P., Birley, J.L. Psychopharmacology (Berl.) (1977) [Pubmed]
  21. Severe aggression in rats induced by mescaline but not other hallucinogens. Sbordone, R.J., Wingard, J.A., Gorelick, D.A., Elliott, M.L. Psychopharmacology (Berl.) (1979) [Pubmed]
  22. Effects of iproniazid and tranylcypromine of the half-life of N,N-dimethyltryptamine in rat brain and liver. Wang Lu, L.J., Domino, E. Biochem. Pharmacol. (1976) [Pubmed]
  23. Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice. Morinan, A., Collier, J.G. Psychopharmacology (Berl.) (1981) [Pubmed]
  24. Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors. Deliganis, A.V., Pierce, P.A., Peroutka, S.J. Biochem. Pharmacol. (1991) [Pubmed]
  25. Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues. Kärkkäinen, J., Forsström, T., Tornaeus, J., Wähälä, K., Kiuru, P., Honkanen, A., Stenman, U.H., Turpeinen, U., Hesso, A. Scand. J. Clin. Lab. Invest. (2005) [Pubmed]
  26. A characteristic effect of hallucinogens on investigatory responding in rats. Geyer, M.A., Light, R.K., Rose, G.J., Petersen, L.R., Horwitt, D.D., Adams, L.M., Hawkins, R.L. Psychopharmacology (Berl.) (1979) [Pubmed]
  27. Indolealkylamines and prolactin secretion. A structure-activity study in the central nervous system of the rat. Seeman, G., Brown, G.M. Neuropharmacology (1985) [Pubmed]
  28. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., Kovar, K.A. Pharmacopsychiatry (2005) [Pubmed]
  29. Spectral analysis of mouse EEG after the administration of N,N-dimethyltryptamine. Morley, B.J., Bradley, R.J. Biol. Psychiatry (1977) [Pubmed]
  30. Hallucinogenic N-methylated indolealkylamines in the cerebrospinal fluid of psychiatric and control populations. Corbett, L., Christian, S.T., Morin, R.D., Benington, F., Smythies, J.R. The British journal of psychiatry : the journal of mental science. (1978) [Pubmed]
  31. Comparison of the brain levels of N,N-dimethyltryptamine and alpha, alpha, beta, beta-tetradeutero-N-N-dimethyltryptamine following intraperitoneal injection. The in vivo kinetic isotope effect. Barker, S.A., Beaton, J.M., Christian, S.T., Monti, J.A., Morris, P.E. Biochem. Pharmacol. (1982) [Pubmed]
  32. Disruption of conditioned avoidance behavior by n,n-dimethyltryptamine (DMT) and stereotype by beta-phenylethylamine (PEA): animal models of attentional defects in schizophrenia. Stoff, D.M., Moja, E.A., Gillin, J.C., Wyatt, R.J. Journal of psychiatric research. (1978) [Pubmed]
  33. Pharmahuasca: human pharmacology of oral DMT plus harmine. Ott, J. Journal of psychoactive drugs. (1999) [Pubmed]
 
WikiGenes - Universities